Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals - a randomized cross-over trial

Biomedicine and Pharmacotherapy

Volumn 68, Issue 8, 2014, Pages 1071-1077

  Miyoshi, Toru ^a   Noda, Yoko ^a   Ohno, Yuko ^a   Sugiyama, Hiroki ^a   Oe, Hiroki ^b   Nakamura, Kazufumi ^a   Kohno, Kunihisa ^a   Ito, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Endothelial dysfunction; Omega 3 fatty acid; Triglyceride

Indexed keywords

CARBOHYDRATE DIET; OMEGA 3 FATTY ACID;

ADMINISTRATION AND DOSAGE; ADULT; ADVERSE EFFECTS; AGED; BLOOD; CARBOHYDRATE DIET; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG EFFECTS; FEMALE; HUMAN; HYPERLIPIDEMIAS; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DIETARY CARBOHYDRATES; ENDOTHELIUM, VASCULAR; FASTING; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; YOUNG ADULT;

EID: 84916217631     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.10.008     Document Type: Article

References (41)

1. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with non-fasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298(3):309-316.
2. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298(3):299-308.
3. Mihas C., Kolovou G.D., Mikhailidis D.P., Kovar J., Lairon D., Nordestgaard B.G., Ooi T.C., Perez-Martinez P., Bilianou H., Anagnostopoulou K., Panotopoulos G. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol 2011, 9(3):271-280.
4. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation 1979, 60(3):473-485.
5. Bae J.H., Bassenge E., Kim K.B., Kim Y.N., Kim K.S., Lee H.J., Moon K.C., Lee M.S., Park K.Y., Schwemmer M. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis 2001, 155(2):517-523.
6. van Oostrom A.J., Sijmonsma T.P., Verseyden C., Jansen E.H., de Koning E.J., Rabelink T.J., Castro Cabezas M. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res 2003, 44(3):576-583.
7. Lombardo Y.B., Chicco A.G. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J Nutr Biochem 2006, 17(1):1-13.
8. Roche H.M., Gibney M.J. Long-chain n-3 polyunsaturated fatty acids and triacylglycerol metabolism in the postprandial state. Lipids 1999, 34(Suppl):S259-S265.
9. Balk E.M., Lichtenstein A.H., Chung M., Kupelnick B., Chew P., Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006, 189(1):19-30.
10. Nestel P.J., Connor W.E., Reardon M.F., Connor S., Wong S., Boston R. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 1984, 74(1):82-89.
11. Harris W.S. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997, 65(5 Suppl):1645S-1654S.
12. Maki K.C., Lawless A.L., Kelley K.M., Dicklin M.R., Schild A.L., Rains T.M. Prescription omega-3-acid ethyl esters reduce fasting and postprandial triglycerides and modestly reduce pancreatic beta-cell response in subjects with primary hypertriglyceridemia. Prostaglandins Leukot Essent Fatty Acids 2011, 85(3-4):143-148.
13. Schirmer S.H., Werner C.M., Binder S.B., Faas M.E., Custodis F., Bohm M., Laufs U. Effects of omega-3 fatty acids on postprandial triglycerides and monocyte activation. Atherosclerosis 2012, 225(1):166-172.
14. Diagnosis, classification of diabetes mellitus Diabetes Care 2005, 28(Suppl 1):S37-S42.
15. Japan Atherosclerosis Society Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases. J Atheroscler Thromb 2007, 5-57.
16. Yunoki K., Nakamura K., Miyoshi T., Enko K., Kohno K., Morita H., Kusano K.F., Ito H. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis 2011, 217(2):486-491.
17. Harano Y., Miyawaki T., Nabiki J., Shibachi M., Adachi T., Ikeda M., Ueda F., Nakano T. Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. Endocrine J 2006, 53(2):173-180.
18. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., Deanfield J., Drexler H., Gerhard-Herman M., Herrington D., Vallance P., Vita J., Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39(2):257-265.
19. Chan S.Y., Mancini G.B., Kuramoto L., Schulzer M., Frohlich J., Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol 2003, 42(6):1037-1043.
20. Usui S., Hara Y., Hosaki S., Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 2002, 43(5):805-814.
21. Olijhoek J.K., Hajer G.R., van der Graaf Y., Dallinga-Thie G.M., Visseren F.L. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J Cardiovasc Pharmacol 2008, 52(2):145-150.
22. Miyoshi T., Nakamura K., Yoshida M., Miura D., Oe H., Akagi S., Sugiyama H., Akazawa K., Yonezawa T., Wada J., Ito H. Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats. Cardiovasc Diabetol 2014, 13:43.
23. Skulas-Ray A.C., Kris-Etherton P.M., Harris W.S., Vanden Heuvel J.P., Wagner P.R., West S.G. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 2011, 93(2):243-252.
24. Hassanali Z., Ametaj B.N., Field C.J., Proctor S.D., Vine D.F. Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat. Diabetes Obes Metab 2010, 12(2):139-147.
25. Fahs C.A., Yan H., Ranadive S., Rossow L.M., Agiovlasitis S., Wilund K.R., Fernhall B. The effect of acute fish-oil supplementation on endothelial function and arterial stiffness following a high-fat meal. Appl Physiol Nutr Metab 2010, 35(3):294-302.
26. Levy E., Spahis S., Ziv E., Marette A., Elchebly M., Lambert M., Delvin E. Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids. Diabetologia 2006, 49(8):1937-1945.
27. Harris W.S., Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides?. Curr Opin Lipidol 2006, 17(4):387-393.
28. Ikeda I., Kumamaru J., Nakatani N., Sakono M., Murota I., Imaizumi K. Reduced hepatic triglyceride secretion in rats fed docosahexaenoic acid-rich fish oil suppresses postprandial hypertriglyceridemia. J Nutr 2001, 131(4):1159-1164.
29. Park Y., Harris W.S. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003, 44(3):455-463.
30. 2 cells. J Lipid Res 1992, 33(9):1281-1293.
31. Nakajima K., Nakano T., Tokita Y., Nagamine T., Inazu A., Kobayashi J., Mabuchi H., Stanhope K.L., Havel P.J., Okazaki M., Ai M., Tanaka A. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin Chim Acta 2011, 412(15-16):1306-1318.
32. Nakajima K., Nakano T., Tokita Y., Nagamine T., Yatsuzuka S., Shimomura Y., Tanaka A., Sumino H., Nara M., Machida T., Murakami M. The characteristics of remnant lipoproteins in the fasting and postprandial plasma. Clin Chim Acta 2012, 413(13-14):1077-1086.
33. Park Y., Jones P.G., Harris W.S. Triacylglycerol-rich lipoprotein margination: a potential surrogate for whole-body lipoprotein lipase activity and effects of eicosapentaenoic and docosahexaenoic acids. Am J Clin Nutr 2004, 80(1):45-50.
34. Chin J.P., Gust A.P., Nestel P.J., Dart A.M. Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension 1993, 21(1):22-28.
35. Mori T.A., Watts G.F., Burke V., Hilme E., Puddey I.B., Beilin L.J. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000, 102(11):1264-1269.
36. McVeigh G.E., Brennan G.M., Johnston G.D., McDermott B.J., McGrath L.T., Henry W.R., Andrews J.W., Hayes J.R. Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993, 36(1):33-38.
37. Norata G.D., Grigore L., Raselli S., Redaelli L., Hamsten A., Maggi F., Eriksson P., Catapano A.L. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007, 193(2):321-327.
38. Friedberg C.E., Janssen M.J., Heine R.J., Grobbee D.E. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care 1998, 21(4):494-500.
39. Montori V.M., Farmer A., Wollan P.C., Dinneen S.F. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 2000, 23(9):1407-1415.
40. Woodman R.J., Mori T.A., Burke V., Puddey I.B., Watts G.F., Beilin L.J. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002, 76(5):1007-1015.
41. Satoh N., Shimatsu A., Kotani K., Sakane N., Yamada K., Suganami T., Kuzuya H., Ogawa Y. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 2007, 30(1):144-146.